For more than twenty years, the Aplastic Anemia and MDS International Foundation (AAMDISF) has provided investigators with financial support for research that leads to new insights into the causes of bone marrow failure and the development of new therapeutic approaches.
To be eligible to apply for a research grant, an applicant must hold a Doctor of Medicine, Doctor of Osteopathy, Doctor of Philosophy, Doctor of Science, or other doctoral level degree (e.g., PharmD). There are no nationality restrictions. Research may be carried out in the United States or abroad but not at a for-profit laboratory in the private sector. The project must represent independent research conducted by the applicant.
Grants can be awarded to New Investigators and Established Investigators. New Investigators are post-doctoral fellows, instructors and those who have been assistant professors for fewer than five (5) years. Established Investigators have been assistant professors for five (5) years or more or are associate or full professors.
Preference will be given to applications submitted by New Investigators who propose a project that will contribute toward their professional development in bone marrow failure disease research.
Applications are reviewed by members of the AAMDSIF Medical Advisory Board. Awards are based on the scientific quality of the research plan, the relevance of the proposed research to the Foundation's goals, the applicant’s qualifications and the quality of the research institution and facility where the research will be conducted. In the case of New Investigators, the quality and support of the research mentor also will be considered.
Topic areas considered for funding include:
- Promoting understanding of the etiology and pathogenesis of aplastic anemia, MDS or PNH;
- Improving symptom management and the quality of life for aplastic anemia, MDS or PNH patients;
- Discovering new treatments for aplastic anemia, MDS or PNH;
- Understanding and preventing complications of bone marrow failure conditions (e.g., blood clotting/thrombosis in PNH, iron overload in MDS, etc.); and,
- Research regarding inherited bone marrow failure disorders, provided a strong case is also made for pertinence of the research to acquired disorders.
- In addition, the following criteria will be considered by reviewers:
- The likelihood that the goals of the proposal are attainable with the funding from AAMDSIF;
- The project is independent research and not part of a large, multi-funded study;
- The translational nature of the research and whether the findings can be rapidly applied to benefit patients; and,
- For New Investigators, the likelihood that the project will contribute toward the professional development of the researcher.
Applications that do not fall within the selection criteria, or that address a disease outside of our scope (e.g., acute leukemia), will be disqualified.
Application Due Date
Applications will be accepted from January 3, 2017 through February 28, 2017. Detailed criteria and applications instructions are available at proposalCENTRAL. All applications are submitted online using proposalCENTRAL.
Amount of Foundation Support
Successful applicants can be funded up to $60,000 for two years ($30,000 each year, with second-year funding pending approved progress in the first year). Grant funds may be used only to support the direct costs of research and indirect costs of up to 10% of the grant.
Support from Other Sources
An applicant may not apply for, use, or accept AAMDSIF funds for a research project or part of a project already supported by AAMDSIF. Accordingly, full disclosure of all available and pending funds for research support must be made in the budget included with the grant application. If funds from other sources become available to the applicant during the review or tenure of an AAMDSIF research grant, the principal investigator must inform AAMDSIF in writing. AAMDSIF and its advisors will then make a decision about the continuation of the research award.
Change in Status
The continued use of grant funds following any change in the status of the principal investigator requires approval in writing by AAMDSIF. Such changes include, but are not limited to, a move by the investigator to a new institution, the institution’s withdrawal from the project, the investigator’s termination from the institution, or an absence of the grantee longer than six weeks. Because the grant is awarded to the investigator and not to the institution, upon AAMDSIF approval, grant funds remain with the principal investigator.
A financial report form will be mailed to the grantee's financial officer with a copy of the award letter. The completed form must be returned to AAMDSIF within twelve (12) weeks after the termination date of the award.
A final report is due to AAMDSIF six weeks after the close of the award period. Reprints of any publication written by the grant recipient and relating to the work performed during the award period must be included.
A one-page lay-language summary intended for patients must be submitted for the Foundation’s use in its website, newsletters, annual reports and other material.
Human and/or Animal Subjects/Tissues
Appropriate IRB documentation is required when human subjects or tissues, or animals and/or animal tissues are to be used in a research project. It is the responsibility of the grantee and the institution to ensure that the institution can produce the complete research protocol approved by the IRB. A copy of these documents must also be submitted with the application or delivered upon notice of award and before grant funds are transmitted.
Conflict of Interest
Any real or potential conflict of interest on the part of the grantee or any collaborators/mentors in relation to the project must be revealed. It is expected that AAMDSIF grantees will observe the highest ethical standards while conducting research.
TERMS OF THIS POLICY ARE SUBJECT TO REVISION OR ALTERATION AT ANY TIME.
Contact Ellen J. Salkeld, PhD, Senior Director of Research at email@example.com or (301) 279-7202
AAMDSIF research grants are made possible by the generous contributions of patients, families and friends.